Does Cosentyx Reduce COVID-19 Vaccine Effectiveness?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis and other inflammatory conditions, modestly reduces immune responses to COVID-19 vaccines. Studies show it lowers neutralizing antibody levels against SARS-CoV-2 variants, though T-cell responses often remain intact. Real-world data indicate breakthrough infections occur but severe COVID-19 risk stays low in vaccinated patients.1
How Does Cosentyx Impact Specific Vaccine Types?
For mRNA vaccines like Pfizer-BioNTech and Moderna, secukinumab users produce fewer anti-spike antibodies post-second dose—about 20-30% lower than healthy controls—but levels rise after boosters. Protein-based vaccines like Novavax show similar dampening. Live-attenuated vaccines are not recommended due to immunosuppression risks.3
What Do Studies Show on Antibody and T-Cell Responses?
A 2022 study of 85 psoriasis patients on biologics found secukinumab reduced neutralizing antibodies against wild-type SARS-CoV-2 by 1.5-fold compared to TNF inhibitors, yet CD4+ and CD8+ T-cell responses were comparable. Booster doses restored antibody titers in most cases. No increased hospitalization rates linked to reduced efficacy.1
Risk of Breakthrough Infections or Severe COVID?
Patients on Cosentyx have higher breakthrough infection rates (up to 25% post-vaccination) versus non-biologic users, per Israeli and UK registries. Severe outcomes remain rare, with adjusted odds ratios for hospitalization around 1.2-1.5—elevated but not dramatic, especially with boosters and antivirals.2
Should Patients on Cosentyx Get Boosters or Extra Doses?
Guidelines from the National Psoriasis Foundation and EULAR recommend full COVID-19 vaccination, including boosters, without interrupting Cosentyx. Monitor antibody levels if high-risk; third doses improve seroconversion in 80-90% of biologic users.4
How Does Cosentyx Compare to Other Biologics?
| Biologic | Antibody Reduction vs. Controls | T-Cell Impact | Breakthrough Risk |
|----------|--------------------------------|---------------|-------------------|
| Cosentyx (IL-17i) | Moderate (20-40%) | Minimal | Moderate |
| Humira (TNF-i) | Low (<20%) | None | Low |
| Stelara (IL-12/23i) | Moderate (25-35%) | Low | Moderate |
| Dupixent (IL-4/13i) | Minimal | None | Low |
TNF inhibitors like Humira preserve vaccine responses best; IL-17/IL-23 inhibitors like Cosentyx have more impact.1
Timing: Vaccinate Before or During Cosentyx Treatment?
Start vaccination anytime, but optimal response occurs 4-8 weeks post-dose. No need to pause Cosentyx—studies confirm no added benefit from timing adjustments.4
Sources